Literature DB >> 9142180

Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.

I Takanami1, F Tanaka, T Hashizume, S Kodaira.   

Abstract

BACKGROUND: In the United States, pulmonary adenocarcinomas have recently replaced squamous cell carcinomas as the most frequent type of lung cancer encountered. The incidence of pulmonary adenocarcinoma continued to increase worldwide.
METHOD: To determine the roles of the transforming growth factor-beta 1 (TGF-beta 1), and TGF-beta type I receptor (T beta R-I), and the TGF-beta type II receptor (T beta R-II) in the progression of a pulmonary adenocarcinoma, their respective expressions have been immunohistologically studied in specimens from 120 pulmonary adenocarcinoma patients. RESULT: The overall prognosis was significantly poorer for patients showing positive TGF-beta 1, T beta R-I, T beta R-II expressions than for patients who were negative to all three immunostainings (P < 0.01). Our multivariate analysis also revealed that a positive TGF-beta 1 response significantly affect prognosis (P < 0.05).
CONCLUSIONS: TGF-beta 1, T beta R-I, and T beta R-II play important roles in tumor progression, and a positive TGF-beta 1 expression can serve as a pulmonary adenocarcinoma marker. T beta R-I and T beta R-II expressions are necessary for TGF-beta signal transduction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142180     DOI: 10.1002/(sici)1096-9098(199704)64:4<262::aid-jso3>3.0.co;2-7

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.

Authors:  Douglas S Micalizzi; Chu-An Wang; Susan M Farabaugh; William P Schiemann; Heide L Ford
Journal:  Cancer Res       Date:  2010-11-05       Impact factor: 12.701

3.  TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer.

Authors:  Paula Fernanda Vázquez; María José Carlini; María Cecilia Daroqui; Lucas Colombo; Mercedes Liliana Dalurzo; David Eduardo Smith; Julieta Grasselli; María Guadalupe Pallotta; Marcelo Ehrlich; Elisa Dora Bal de Kier Joffé; Lydia Puricelli
Journal:  Clin Exp Metastasis       Date:  2013-07-06       Impact factor: 5.150

4.  Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell lung cancer.

Authors:  Yuanyuan Gao; Yan Wang; Lichun Sun; Qingwei Meng; Li Cai; Xiaoqun Dong
Journal:  Tumour Biol       Date:  2014-06-20

5.  Expression and significance of transforming growth factor-β receptor type II and DPC4/Smad4 in non-small cell lung cancer.

Authors:  Hong Chen; Jing-Wei Wang; Li-Xin Liu; Ji-Dong Yan; Shu-Hua Ren; Yan Li; Zheng Lu
Journal:  Exp Ther Med       Date:  2014-11-12       Impact factor: 2.447

6.  TGF-beta 1 levels are associated with lymphocyte percentages in patients with lung cancer treated with radiation therapy.

Authors:  Jing Luo; Sainan Hu; Tingting Wei; Jifeng Sun; Ningbo Liu; Jun Wang
Journal:  Onco Targets Ther       Date:  2018-11-26       Impact factor: 4.147

7.  Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer.

Authors:  Dong Park; Hee Jung Son; Sang Yong Song; Won Hyeok Choe; Yun Jeong Lim; Sang Jong Park; Jae J Kim; Young Ho Kim; Poong Lyul Rhee; Seung Woon Paik; Jong Chul Rhee; Kyoo Wan Choi
Journal:  Korean J Intern Med       Date:  2002-09       Impact factor: 2.884

8.  Clinical Implications of TβRII Expression in Breast Cancer.

Authors:  Ningning Gao; Qixi Zhai; Yinyan Li; Kun Huang; Donglin Bian; Xuemei Wang; Caigang Liu; Hong Xu; Teng Zhang
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.